SAB Biotherapeutics Confirms Positive Phase 1 Results for SAB-142, Advancing to Phase 2b Trial for Type 1 Diabetes Treatment
Phase 1 data confirms SAB-142 does not cause serum sickness and has low/no immunogenicity at any dose and in all cohorts, including redosed healthy volunteers Study results support the chronic…